本頁面由Tiger Trade Technology Pte. Ltd.提供服務

諾和諾德

36.33
-0.5600-1.52%
盤前35.88-0.4500-1.24%06:41 EDT
成交量:1,644.27萬
成交額:6.04億
市值:1,612.71億
市盈率:10.03
高:37.39
開:37.15
低:36.23
收:36.89
52周最高:81.44
52周最低:35.85
股本:44.39億
流通股本:31.88億
量比:0.78
換手率:0.52%
股息:1.72
股息率:4.74%
每股收益(TTM):3.62
每股收益(LYR):3.62
淨資產收益率:60.70%
總資產收益率:17.43%
市淨率:5.65
市盈率(LYR):10.03

資料載入中...

2026/02/04

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/06/27

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/06/27

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2025/05/30

關聯方擬減持公告

Form 144 | Innate Pharma SA 10% 股東 Novo Nordisk A/S 擬減持921897股,總價約197萬美元
2025/02/05

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/21

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/06/21

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2024/01/31

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/11/24

SEC問詢函

Form CORRESP - Correspondence
2023/11/09

SEC問詢函

Form CORRESP - Correspondence
2023/10/20

SEC問詢函

Form CORRESP - Correspondence
2023/09/29

SEC問詢函

Form CORRESP - Correspondence
2023/09/13

SEC問詢函

Form CORRESP - Correspondence
2023/06/28

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/06/28

員工持股計劃

Form 11-K - Annual report of employee stock purchase, savings and similar plans
2023/02/01

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/06/28

員工持股計劃

11-K [Paper] - Annual report of employee stock purchase, savings and similar plans
2022/06/28

員工持股計劃

11-K [Paper] - Annual report of employee stock purchase, savings and similar plans
2022/03/24

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/02/02

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]